The National Institute for Health and Care Excellence has published a trio of new final guidances, allowing National Health Service use of Boehringer Ingelheim’s Vargatef for lung cancer, AstraZeneca’s Moventig for opioid-induced constipation, and Novartis Cosentyx for plaque psoriasis.

Vargetef (nintedanib) is recommended as an option for treating locally advanced, metastatic or locally recurrent non-small-cell lung cancer that has progressed after first-line chemotherapy, but only if discounts agreed under a Patient Access Scheme are applied.

For more details, go to: http://www.pharmatimes.com/Article/15-07-22/NICE_OKs_trio_of_new_drugs_for_NHS_use.aspx